Skip to main content
Premium Trial:

Request an Annual Quote

Perthera Partners With Lung Cancer Alliance to Provide Free Precision Medicine Services

NEW YORK (GenomeWeb) – Perthera today announced a partnership with the Lung Cancer Alliance under which the parties will provide free precision medicine services to lung cancer patients.

These services include genomic, proteomic, and phosphoproteomic analyses of patient tumors as well as the expertise of medical specialists including oncologists, researchers, and computational biologists, Perthera said.

"Now, more than ever, having detailed knowledge about the characteristics of a tumor is a critical component to determining a patient’s most effective treatment options, and this program makes that a reality no matter where that patient may be," Jennifer King, the Lung Cancer Alliance's director of science and research, said in a statement.

Launched in 2013 by George Mason University researcher Emanuel Petricoin and venture capitalist Dendy Young, McLean, Virginia-based Perthera provides molecular profiling of cancer patients to help physicians guide their treatments.

The company helps patients and their doctors access genomic, proteomic, and phosphoproteomics profiling services from outside companies, serving as an intermediary handling the many steps involved in obtaining and sending out patient tumor samples to molecular profiling firms and returning assay results.